Nuvaira Announces First Patient Treated in RELIEF-1 Study Evaluating New Approach for Asthma Treatment

Nuvaira recently announced treatment of the first patient in the RELIEF-1 Clinical Study in Europe. The RELIEF-1 trial (NCT02872298) is a prospective, multi-center, single-arm (non-randomized) study designed to evaluate the safety and technical feasibility of a procedure called Targeted Lung Denervation (TLD) using the Nuvaira Lung Denervation System for the treatment of severe asthma.

The feasibility study is slated to treat a total of 30 patients at facilities in France, Germany, the Netherlands, and the United Kingdom, with patient follow-up planned out to 3 years. Principal Investigators of RELIEF-1 are Nick ten Hacken, MD, PhD, at the University Medical Center Groningen (UMCG), the Netherlands, and Professor Pallav Shah, MD, at Royal Brompton & Harefield NHS Foundation Trust and Chelsea and Westminster Hospital NHS Foundation Trust in London. Dirk-Jan Slebos, MD, PhD, performed the first patient treatment in the Department of Pulmonary Diseases at UMCG.

“The first patient tolerated the minimally invasive therapeutic treatment very well, and there were no procedural complications,” according to Dr. ten Hacken. “TLD is the first medical procedure that targets the whole lung by disrupting the overactive nerves into the lungs, thereby opening up the airways and making it easier to breathe. We are encouraged by how well the first patient responded to TLD and we look forward to treating additional asthma patients utilizing this innovative, one-time procedure.”

The Nuvaira Lung Denervation System is a catheter-based system developed to treat patients with obstructive lung disease, specifically severe asthma and chronic obstructive pulmonary disease (COPD). The system’s proprietary technology delivers targeted energy to disrupt nerve signals to the lungs using a process known as denervation. The simple, one-time bronchoscopic treatment has the potential to provide lasting whole lung improvement for severe asthma patients by opening obstructed airways to make breathing easier. Currently, there is no cure for asthma, but there are treatment plans that can help patients manage the disease. Approximately three quarters of asthma sufferers are adults, with 10% suffering from severe asthma, which is difficult to treat.

“The first patient treatment in our RELIEF-1 Clinical Trial is an important milestone in our quest to develop a safe and effective treatment for asthma patients worldwide,” said Dennis Wahr, MD, Chief Executive Officer at Nuvaira. “Earlier trials evaluating TLD in COPD patients have demonstrated feasibility and promising long-term, sustained treatment results. We look forward to the completion of this important study.”

Nuvaira (formerly known as Holaira) is a privately held company headquartered in Minneapolis, MN. The company is developing the Nuvaira Lung Denervation System to address chronic obstructive pulmonary disease (COPD) and asthma by treating the overactive airway nerves during Targeted Lung Denervation (TLD). Nuvaira received CE Mark approval for its Nuvaira Lung Denervation System for the treatment of COPD in January 2016. For more information, visit www.Nuvaira.com.